This is a preview of subscription content, log in via an institution to check access.
References
Mitchell DY, Vandenouweland FA, Heise MA, et al. Effect of food on risedronate pharmacokinetics in healthy volunteers. Pharmaceut Res 1994 Oct; 11 Suppl: 370
Eastell R, Devogelaer JP, Pell NFA, et al. Risedronate therapy prevents bone loss in glucocorticoid-treated rheumatoid arthritis patients: a three-year study. Inflammopharmacology 1997 Jun; 5: 186–8
Wronski TJ, Yen CF, Qi H, et al. Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats. Endocrinology 1993 Feb; 132: 823–31
Boyce RW, Paddock CL, Franks AF, et al. Effects of intermittent hPTH(1–34) alone and in combination with 1,25(OH)(2)D-3 or risedronate on endosteal bone remodeling in canine cancellous and cortical bone. J Bone Miner Res May 1996; 11: 600–13
Delmas PD, Balena R, Confravreux E, et al. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 1997 Mar; 15: 955–62
Rights and permissions
About this article
Cite this article
Risedronic Acid. Drugs R&D 1, 218–220 (1999). https://doi.org/10.2165/00126839-199901030-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-199901030-00006